ABSTRACT OF THE DISCLOSURE

Novel sulfate ester agents and the use of those agents for treating gastroesophageal reflux disease (GERD) are described, exemplary agents being of the formula:

$$\mathbb{R}^{2}_{(n)}$$
 \mathbb{X}
 $\mathbb{R}^{1}_{(n)}$

wherein X is -OCH₂- or -CH₂O-; Y is a group pendant from X comprising at least one -OSO₃R⁴ moiety, wherein R⁴ is H or a pharmaceutically acceptable cation; n is an integer from 1-3; and R¹ and R² are each independently selected from the group consisting of -H, a halogen with an atomic number from 9 to 53, -SO₃R⁴, -NCS, -NCO, -NH(CO)-OR³, -NH(CS)SR³, -NH(C=NH)OR³, -NHCOCH₂Cl, -NHCOCH₂Br, -NHCO-CH=CH₂, -NHC(O)-CF₃, wherein R⁴ is H or a pharmaceutically acceptable cation.